Phase III dose-comparison study of glatiramer acetate for multiple sclerosis
Author:
Publisher
Wiley
Subject
Neurology (clinical),Neurology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/ana.22316/fullpdf
Reference19 articles.
1. A pilot study of COP 1 in exacerbating-remitting multiple sclerosis;Bornstein;N Engl J Med,1987
2. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability;Johnson;Neurology,1998
3. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group;Comi;Ann Neurol,2001
4. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated sindrome (PreCISe study): a randomised, double-blind, placebo-controlled trial;Comi;Lancet,2009
5. The mechanism of action of glatiramer acetate treatment in multiple sclerosis;Racke;Neurology,2010
Cited by 59 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-01-04
2. Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-11-30
3. Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders;Autoimmunity Reviews;2023-05
4. Hiding in plain sight: The magnitude of unused disease modifying therapies in multiple sclerosis and strategies for reducing the economic burden of care;Multiple Sclerosis and Related Disorders;2022-07
5. Therapeutic Advances in Multiple Sclerosis;Frontiers in Neurology;2022-06-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3